Plain-English translation of NCT06648889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat adult patients with a serious blood cancer called T-cell acute lymphoblastic leukemia (T-ALL) that has either come back after treatment or never responded to chemotherapy in the first place. The study has two groups: one for patients whose cancer has clearly returned or is resistant to treatment, and another for patients whose cancer appears to be in remission by standard tests but shows signs of remaining disease at a molecular level. Researchers hope this treatment can help patients when standard options have stopped working.
T-ALL is an aggressive blood cancer, and many patients either relapse (the cancer comes back) or have cancer that doesn't respond to standard chemotherapy. Currently, there are limited treatment options for these patients once they reach this point. This trial is designed to see whether this medication can offer a new hope for people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as part of either combination chemotherapy (if your cancer has visibly returned) or as a single drug (if your cancer appears in remission but shows molecular signs of disease). You will have regular clinic visits for treatment administration, blood tests to monitor your response and side effects, and bone marrow or blood samples to check whether the cancer is responding. The study will carefully track your safety and how well the treatment works over time.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Germany